News | August 04, 2022
Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
The company has responded to the warning letter and carried out the committed corrections.
Strides is the first Indian company to get approval for the product.
he US FDA has issued six observations pursuant to the completion of the audit.
He was appointed a Board member and the Chairman in 2012.
The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
